Xtl Biopharmaceuticals (XTLB) Cash from Operations Growth (3y) (2012 - 2016)
Xtl Biopharmaceuticals (XTLB) Cash from Operations Growth (3y) (2012 - 2016) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 33.08% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 8.72% |
| Dec 31, 2015 | 124.70% |
| Sep 30, 2015 | 2.39% |
| Jun 30, 2015 | -14.32% |
| Dec 31, 2014 | -70.50% |
| Sep 30, 2014 | -22.75% |
| Jun 30, 2014 | -17.66% |
| Mar 31, 2014 | -24.90% |
| Dec 31, 2013 | -22.63% |
| Sep 30, 2013 | -53.64% |
| Jun 30, 2013 | -83.00% |
| Mar 31, 2013 | -60.00% |
| Dec 31, 2012 | -45.26% |
| Sep 30, 2012 | -26.08% |
| Jun 30, 2012 | -44.51% |
| Mar 31, 2012 | 40.22% |